azd-7325
Clinical trial activity
15 trials · 10 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2008 (NCT00681720)
Timeline
Indications
Mechanism of action
- GABA receptor alpha-3 subunitPOSITIVE ALLOSTERIC MODULATOR
GABRA3 positive allosteric modulator
Discontinued by AstraZeneca but in trials by other sponsors. Compound is listed in AstaZeneca's clinical and/or preclinical compound bank and available for research projects.
Binding affinity is high at GABAAa1, a2 and a3 (Ki of 0.5, 0.3 and 1.3 nM, respectively), but not GA
- GABA receptor alpha-2 subunitPOSITIVE ALLOSTERIC MODULATOR
GABRA2 positive allosteric modulator
Discontinued by AstraZeneca but in trials by other sponsors. Compound is listed in AstaZeneca's clinical and/or preclinical compound bank and available for research projects.
Binding affinity is high at GABAAa1, a2 and a3 (Ki of 0.5, 0.3 and 1.3 nM, respectively), but not GA
Chemistry & pharmacology
SMILES
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N- Mol. weight
- 354.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1783282 ↗
Also known as
- 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3-carboxamide
- azd7325
- azd7325
- azd7325
- azd7325
- azd-7325
- azd-7325
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03140813 | Phase 1 | May 1, 2017 | University of Cincinnati |
| NCT02530580 | Phase 1 | Feb 1, 2016 | University of London |
| NCT02135198 | Phase 1 | Sep 1, 2014 | University of London |
| NCT01966679 | Phase 2 | Oct 1, 2013 | University of California, Los Angeles |
| NCT00940641 | Phase 1 | Aug 1, 2009 | AstraZeneca |
| NCT00945425 | Phase 1 | Jul 1, 2009 | AstraZeneca, Kitasato University |
| NCT00901290 | Phase 1 | May 1, 2009 | AstraZeneca, IQVIA |
| NCT00902772 | Phase 1 | May 1, 2009 | AstraZeneca, Kendle International Inc. |
| NCT00808249 | Phase 2 | Dec 1, 2008 | AstraZeneca, University of South Florida |
| NCT00807937 | Phase 2 | Dec 1, 2008 | AstraZeneca |
| NCT00769899 | Phase 1 | Oct 1, 2008 | AstraZeneca, California Clinical Trials |
| NCT00790114 | Phase 1 | Jul 1, 2008 | AstraZeneca, University of London |
| NCT00720421 | Phase 1 | Jun 1, 2008 | AstraZeneca, Leiden University |
| NCT00681915 | Phase 1 | Mar 1, 2008 | AstraZeneca |
| NCT00681720 | Phase 1 | Feb 1, 2008 | AstraZeneca |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 11 | 11 | 2 | 2008 |
| University of London | Academic/Hospital | 3 | 2 | 1 | 2008 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2008 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
| Kendle International Inc. | For profit | 1 | 0 | 1 | 2009 |
| Kitasato University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2008 |